[go: up one dir, main page]

GB2590485B - Nanoparticle conjugation - Google Patents

Nanoparticle conjugation Download PDF

Info

Publication number
GB2590485B
GB2590485B GB1918898.6A GB201918898A GB2590485B GB 2590485 B GB2590485 B GB 2590485B GB 201918898 A GB201918898 A GB 201918898A GB 2590485 B GB2590485 B GB 2590485B
Authority
GB
United Kingdom
Prior art keywords
nanoparticle conjugation
nanoparticle
conjugation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
GB1918898.6A
Other versions
GB201918898D0 (en
GB2590485A (en
Inventor
Leo Van Workum Stefan
Alexander Turek Vladimir
Dorrestijn Marko
R Klug David
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vidya Holdings Ltd
Original Assignee
Vidya Holdings Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vidya Holdings Ltd filed Critical Vidya Holdings Ltd
Priority to GB1918898.6A priority Critical patent/GB2590485B/en
Publication of GB201918898D0 publication Critical patent/GB201918898D0/en
Priority to PCT/GB2020/053285 priority patent/WO2021123806A1/en
Publication of GB2590485A publication Critical patent/GB2590485A/en
Application granted granted Critical
Publication of GB2590485B publication Critical patent/GB2590485B/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/54366Apparatus specially adapted for solid-phase testing
    • G01N33/54373Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A61K47/6927Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
    • A61K47/6929Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y15/00Nanotechnology for interacting, sensing or actuating, e.g. quantum dots as markers in protein assays or molecular motors
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/25Colour; Spectral properties, i.e. comparison of effect of material on the light at two or more different wavelengths or wavelength bands
    • G01N2021/258Surface plasmon spectroscopy, e.g. micro- or nanoparticles in suspension
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/17Systems in which incident light is modified in accordance with the properties of the material investigated
    • G01N21/55Specular reflectivity
    • G01N21/552Attenuated total reflection
    • G01N21/553Attenuated total reflection and using surface plasmons
    • G01N21/554Attenuated total reflection and using surface plasmons detecting the surface plasmon resonance of nanostructured metals, e.g. localised surface plasmon resonance

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Pathology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Nanotechnology (AREA)
  • Investigating Or Analysing Materials By Optical Means (AREA)
GB1918898.6A 2019-12-19 2019-12-19 Nanoparticle conjugation Expired - Fee Related GB2590485B (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
GB1918898.6A GB2590485B (en) 2019-12-19 2019-12-19 Nanoparticle conjugation
PCT/GB2020/053285 WO2021123806A1 (en) 2019-12-19 2020-12-18 Nanoparticle conjugation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1918898.6A GB2590485B (en) 2019-12-19 2019-12-19 Nanoparticle conjugation

Publications (3)

Publication Number Publication Date
GB201918898D0 GB201918898D0 (en) 2020-02-05
GB2590485A GB2590485A (en) 2021-06-30
GB2590485B true GB2590485B (en) 2022-04-13

Family

ID=69322810

Family Applications (1)

Application Number Title Priority Date Filing Date
GB1918898.6A Expired - Fee Related GB2590485B (en) 2019-12-19 2019-12-19 Nanoparticle conjugation

Country Status (2)

Country Link
GB (1) GB2590485B (en)
WO (1) WO2021123806A1 (en)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085911A1 (en) * 2014-11-26 2016-06-02 Washington University Bioplasmonic detection of biomarkers in body fluids using peptide recognition elements

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120101007A1 (en) * 2009-04-08 2012-04-26 Provost Fellows And Scholars Of The College Of The Holy And Undivided Trinity Of Queen Elizebeth Nea Silver nanoplates
US20130189793A1 (en) * 2012-01-20 2013-07-25 Wei Qian Stable Colloidal Suspensions Of Gold Nanoconjugates And The Method For Preparing The Same
KR102654470B1 (en) * 2017-01-30 2024-04-05 조에티스 서비시즈 엘엘씨 Solution-based plasmon specific-binding partner assays and metallic nanostructures

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016085911A1 (en) * 2014-11-26 2016-06-02 Washington University Bioplasmonic detection of biomarkers in body fluids using peptide recognition elements

Also Published As

Publication number Publication date
GB201918898D0 (en) 2020-02-05
WO2021123806A1 (en) 2021-06-24
GB2590485A (en) 2021-06-30

Similar Documents

Publication Publication Date Title
IL278990A (en) Camptothecin conjugates
ZA201904269B (en) Pyrrolobenzodiazepine-antibody conjugates
ZA201705923B (en) Drug conjugates comprising antibodies against claudin 18.2
IL277017A (en) Nanoparticle compositions
PL3544636T3 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201702031D0 (en) Pyrrolobenzodiazepine-antibody conjugates
IL272625A (en) Pyrrolobenzodiazepine conjugates
IL269945B (en) Pyrrolobenzodiazepine conjugates
IL293095B1 (en) Directed conjugation technologies
GB201601004D0 (en) Nanoparticle conjugates
GB202112888D0 (en) Nanoparticle
GB201820626D0 (en) Conjugates
IL288681A (en) Pyrrolobenzodiazepine-antibody conjugates
GB2590485B (en) Nanoparticle conjugation
GB201914728D0 (en) Nanoparticle assembly
GB201906997D0 (en) Conjugates
GB201900735D0 (en) Conjugates
GB201811335D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201811332D0 (en) Pyrroloobenzodiazepine-antibody conjugates
GB201721290D0 (en) Conjugates
GB201719906D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719391D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719393D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201719398D0 (en) Pyrrolobenzodiazepine-antibody conjugates
GB201721337D0 (en) Pyrrolobenzodiazepine conjugates

Legal Events

Date Code Title Description
PCNP Patent ceased through non-payment of renewal fee

Effective date: 20231219